Celularity Inc. (CELU)
Total Valuation
Celularity has a market cap or net worth of $121.98 million. The enterprise value is $165.89 million.
Market Cap | 121.98M |
Enterprise Value | 165.89M |
Important Dates
The next estimated earnings date is Monday, April 1, 2024, after market close.
Earnings Date | Apr 1, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Celularity has 21.78 million shares outstanding. The number of shares has increased by 25.09% in one year.
Shares Outstanding | 21.78M |
Shares Change (YoY) | +25.09% |
Shares Change (QoQ) | +6.66% |
Owned by Insiders (%) | 51.13% |
Owned by Institutions (%) | 14.67% |
Float | 9.43M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 8.25 |
Forward PS | n/a |
PB Ratio | 4.03 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 11.22 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.20, with a Debt / Equity ratio of 2.02.
Current Ratio | 0.20 |
Quick Ratio | 0.25 |
Debt / Equity | 2.02 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -76.12 |
Financial Efficiency
Return on equity (ROE) is -144.20% and return on invested capital (ROIC) is -378.09%.
Return on Equity (ROE) | -144.20% |
Return on Assets (ROA) | -62.20% |
Return on Capital (ROIC) | -378.09% |
Revenue Per Employee | $65,724 |
Profits Per Employee | -$806,258 |
Employee Count | 225 |
Asset Turnover | 0.05 |
Inventory Turnover | 0.63 |
Taxes
In the past 12 months, Celularity has paid $13,000 in taxes.
Income Tax | 13,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.44% in the last 52 weeks. The beta is 0.24, so Celularity's price volatility has been lower than the market average.
Beta (1Y) | 0.24 |
52-Week Price Change | -4.44% |
50-Day Moving Average | 4.02 |
200-Day Moving Average | 3.58 |
Relative Strength Index (RSI) | 58.93 |
Average Volume (30 Days) | 287,403 |
Short Selling Information
The latest short interest is 466,640, so 2.14% of the outstanding shares have been sold short.
Short Interest | 466,640 |
Short Previous Month | 3.75M |
Short % of Shares Out | 2.14% |
Short % of Float | 4.95% |
Short Ratio (days to cover) | 3.86 |
Income Statement
In the last 12 months, Celularity had revenue of $14.79 million and -$181.41 million in losses. Loss per share was -$10.20.
Revenue | 14.79M |
Gross Profit | -3.70M |
Operating Income | -345.29M |
Pretax Income | -181.40M |
Net Income | -181.41M |
EBITDA | -169.66M |
EBIT | -179.04M |
Loss Per Share | -$10.20 |
Balance Sheet
The company has $17.17 million in cash and $61.08 million in debt, giving a net cash position of -$43.91 million or -$2.02 per share.
Cash & Cash Equivalents | 17.17M |
Total Debt | 61.08M |
Net Cash | -43.91M |
Net Cash Per Share | -$2.02 |
Equity / Book Value | 30.25M |
Book Value Per Share | 1.39 |
Working Capital | -68.13M |
Cash Flow
In the last 12 months, operating cash flow was -$63.93 million and capital expenditures -$1.25 million, giving a free cash flow of -$65.18 million.
Operating Cash Flow | -63.93M |
Capital Expenditures | -1.25M |
Free Cash Flow | -65.18M |
FCF Per Share | -$3.46 |
Margins
Gross margin is -25.05%, with operating and profit margins of -2,334.95% and -1,226.72%.
Gross Margin | -25.05% |
Operating Margin | -2,334.95% |
Pretax Margin | -1,226.64% |
Profit Margin | -1,226.72% |
EBITDA Margin | -1,147.25% |
EBIT Margin | -1,210.73% |
FCF Margin | -440.74% |
Dividends & Yields
Celularity does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -25.09% |
Shareholder Yield | -25.09% |
Earnings Yield | -148.71% |
FCF Yield | -53.43% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 29, 2024. It was a reverse split with a ratio of 1:10.
Last Split Date | Feb 29, 2024 |
Split Type | Reverse |
Split Ratio | 1:10 |
Scores
Celularity has an Altman Z-Score of -11.19 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -11.19 |
Piotroski F-Score | 3 |